Format
Sort by
Items per page

Send to

Choose Destination

Best matches for NAFLD vitamin E:

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Caldwell S et al. Clin Mol Hepatol. (2017)

The Role of Vitamin E in the Treatment of NAFLD. Perumpail BJ et al. Diseases. (2018)

Therapies in non-alcoholic steatohepatitis (NASH). Oseini AM et al. Liver Int. (2017)

Search results

Items: 1 to 20 of 335

1.

How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

Libman H, Jiang ZG, Tapper EB, Reynolds EE.

Ann Intern Med. 2019 Aug 6;171(3):199-207. doi: 10.7326/M19-1125.

PMID:
31382287
2.

Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations.

Arrese M, Barrera F, Triantafilo N, Arab JP.

Expert Rev Gastroenterol Hepatol. 2019 Aug 8:1-18. doi: 10.1080/17474124.2019.1649981. [Epub ahead of print]

PMID:
31353974
4.

Association Between Index of Nutritional Quality and Nonalcoholic Fatty Liver Disease: The Role of Vitamin D and B Group.

Vahid F, Hekmatdoost A, Mirmajidi S, Doaei S, Rahmani D, Faghfoori Z.

Am J Med Sci. 2019 Jul 1. pii: S0002-9629(19)30258-7. doi: 10.1016/j.amjms.2019.06.008. [Epub ahead of print]

PMID:
31326093
5.

Nonalcoholic Fatty Liver Disease: The Overlooked Complication of Type 2 Diabetes.

Akshintala D, Chugh R, Amer F, Cusi K.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2019 Jul 9.

6.

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions.

Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F.

Diabetes Metab Syndr Obes. 2019 Jul 3;12:1001-1012. doi: 10.2147/DMSO.S212715. eCollection 2019.

7.

Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease.

Ivancovsky-Wajcman D, Fliss-Isakov N, Salomone F, Webb M, Shibolet O, Kariv R, Zelber-Sagi S.

Dig Liver Dis. 2019 Jul 4. pii: S1590-8658(19)30662-0. doi: 10.1016/j.dld.2019.06.005. [Epub ahead of print]

PMID:
31281067
8.

Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.

Svegliati-Baroni G, Pierantonelli I, Torquato P, Marinelli R, Ferreri C, Chatgilialoglu C, Bartolini D, Galli F.

Free Radic Biol Med. 2019 May 29. pii: S0891-5849(19)30326-0. doi: 10.1016/j.freeradbiomed.2019.05.029. [Epub ahead of print] Review.

PMID:
31152791
9.

Fatty liver disease in persons with HIV infection.

Seth A, Sherman KE.

Top Antivir Med. 2019 May;27(2):75-82.

10.

Efficacy of dietary intervention and physical activity in children and adolescents with nonalcoholic fatty liver disease associated with obesity: A scoping review.

Caro-Sabido EA, Larrosa-Haro A.

Rev Gastroenterol Mex. 2019 Apr - Jun;84(2):185-194. doi: 10.1016/j.rgmx.2019.02.001. Epub 2019 May 15. Review. English, Spanish.

11.

Vitamin E Ameliorates Lipid Metabolism in Mice with Nonalcoholic Fatty Liver Disease via Nrf2/CES1 Signaling Pathway.

He W, Xu Y, Ren X, Xiang D, Lei K, Zhang C, Liu D.

Dig Dis Sci. 2019 May 10. doi: 10.1007/s10620-019-05657-9. [Epub ahead of print]

PMID:
31076985
12.

Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis.

Pingitore P, Sasidharan K, Ekstrand M, Prill S, Lindén D, Romeo S.

Int J Mol Sci. 2019 Apr 2;20(7). pii: E1629. doi: 10.3390/ijms20071629.

13.

Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block.

Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS.

Curr Vasc Pharmacol. 2019 Apr 5. doi: 10.2174/1570161117666190405164313. [Epub ahead of print]

PMID:
30961499
14.

Nonalcoholic Fatty Liver Disease and Obesity Treatment.

Brunner KT, Henneberg CJ, Wilechansky RM, Long MT.

Curr Obes Rep. 2019 Sep;8(3):220-228. doi: 10.1007/s13679-019-00345-1. Review.

PMID:
30945129
15.

From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.

Moore JB.

Proc Nutr Soc. 2019 Aug;78(3):290-304. doi: 10.1017/S0029665119000570. Epub 2019 Mar 29.

16.

Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.

Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V.

Eur J Gastroenterol Hepatol. 2019 May;31(5):613-617. doi: 10.1097/MEG.0000000000001369.

PMID:
30920975
17.

Allopurinol potentiates the hepatoprotective effect of metformin and vitamin E in fructose-induced fatty liver in rats.

Khalaf HM, Ibrahim MA, Amin EF, Abdel-Tawab Ibrahim S, Abdel-Wahab S, Fouad YM.

Clin Exp Hepatol. 2019 Mar;5(1):65-74. doi: 10.5114/ceh.2019.83159. Epub 2019 Feb 20.

18.

Role of vitamin E in nonalcoholic fatty liver disease.

Nagashimada M, Ota T.

IUBMB Life. 2019 Apr;71(4):516-522. doi: 10.1002/iub.1991. Epub 2018 Dec 27. Review.

PMID:
30592129
19.

The Antioxidant Effects of Hydroxytyrosol and Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease, in a Clinical Trial: A New Treatment?

Nobili V, Alisi A, Mosca A, Crudele A, Zaffina S, Denaro M, Smeriglio A, Trombetta D.

Antioxid Redox Signal. 2019 Jul 10;31(2):127-133. doi: 10.1089/ars.2018.7704. Epub 2019 Feb 11.

PMID:
30588836
20.

The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.

Hosseinpour-Arjmand S, Amirkhizi F, Ebrahimi-Mameghani M.

J Clin Pharm Ther. 2019 Apr;44(2):258-267. doi: 10.1111/jcpt.12784. Epub 2018 Dec 25.

PMID:
30585337

Supplemental Content

Loading ...
Support Center